Sigma Chemopharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 16-11-2024
- Paid Up Capital ₹ 1.50 M
as on 16-11-2024
- Company Age 18 Year, 25 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.40 Cr
as on 16-11-2024
- Satisfied Charges ₹ 5.00 M
as on 16-11-2024
- Revenue 22.86%
(FY 2023)
- Profit -76.12%
(FY 2023)
- Ebitda -30.41%
(FY 2023)
- Net Worth 3.49%
(FY 2023)
- Total Assets -23.75%
(FY 2023)
About Sigma Chemopharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹1.40 Cr. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Pravinkumar Bhuva, Pravinbhai Pipalia, Jamnadas Sanghani, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24232GJ2006PTC049457
- Company No.
049457
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Nov 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sigma Chemopharma?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pravinkumar Bhuva  | Director | 10-Jul-2014 | Current |
| Pravinbhai Pipalia | Director | 30-Sep-2015 | Current |
| Jamnadas Sanghani | Director | 23-Jul-2013 | Current |
| Pankajkumar Antala | Director | 02-Jun-2008 | Current |
| Jaykumar Kanjibhai | Director | 29-Nov-2006 | Current |
| Paresh Antala | Director | 29-Nov-2006 | Current |
Financial Performance of Sigma Chemopharma.
Sigma Chemopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 22.86% increase. The company also saw a substantial fall in profitability, with a 76.12% decrease in profit. The company's net worth moved up by a moderate rise of 3.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sigma Chemopharma?
In 2023, Sigma Chemopharma had a promoter holding of 79.00% and a public holding of 21.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 21 Jul 2015 | ₹6.50 M | Open |
Hdfc Bank Limited Creation Date: 14 Jul 2015 | ₹7.50 M | Open |
Axis Bank Limited Creation Date: 09 Mar 2009 | ₹5.00 M | Satisfied |
How Many Employees Work at Sigma Chemopharma?
Unlock and access historical data on people associated with Sigma Chemopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sigma Chemopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sigma Chemopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
